Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2014-08-27 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
SSAO Inhibitor Ready for the Clinic 2 pages 111.9KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 28 August 2014 from Pharmaxis announcing the completion of preclinical development of a drug candidate and readiness to commence clinical trials. It discusses the drug's potential market and development plans but does not contain financial data, regulatory filings, or detailed financial reports. It is an announcement of a development milestone rather than a financial report or regulatory filing. The document length is 4589 characters, which is relatively short and consistent with a press release. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2014-08-27 English
Preliminary Final Report, Financial and Directors' Report 87 pages 887.4KB
Annual Report Classification · 100% confidence The document is a detailed filing from Pharmaxis Ltd dated 28 August 2014, addressed to the Australian Securities Exchange. It includes an Appendix 4E Preliminary Final Report and the 2014 Directors’ Report and Annual Financial Report for the year ended 30 June 2014. The text contains extensive financial statements, directors' information, auditor's report, and detailed financial data for the full fiscal year. The presence of audited consolidated financial statements and comprehensive management commentary confirms this is a full annual report. The document is lengthy (15,000 characters) and contains the actual report, not just an announcement or a certification. Therefore, the filing type corresponds to an Annual Report (10-K equivalent). FY 2014
2014-08-27 English
Quarter 4 Shareholder Update 7 pages 309.3KB
Annual Report Classification · 95% confidence The document is dated 28 August 2014 and discusses the filing of 2014 financial statements and directors' report with the Australian Securities Exchange. It provides detailed financial data for the quarter and year ending 30 June 2014, including income statement figures, sales performance, R&D expenses, and other financial metrics. The document also discusses business progress, clinical trials, and strategic plans. The presence of comprehensive financial statements and management commentary indicates this is a full annual report covering company activity and financial performance for the fiscal year ending June 2014. It is not a short announcement or a certification, but a substantive report with financial data and analysis. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2014
2014-08-27 English
Pharmaxis Files Lawsuit Against NovaQuest 2 pages 126.0KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX release dated 4 August 2014 announcing that Pharmaxis has filed a lawsuit against NovaQuest for breach of a financing agreement. The content focuses on legal proceedings, allegations of breach, and the company's response, including seeking injunctive relief and damages. There is no financial data, earnings information, or report publication mentioned. The document is clearly about a legal matter involving the company and does not fit into financial reports or announcements about meetings, dividends, or capital changes. Therefore, the most appropriate classification is a Legal Proceedings Report (LTR). The document length is about 4905 characters, which is sufficient for a substantive announcement rather than a brief notice or certification.
2014-08-03 English
Appendix 4C - quarterly 5 pages 106.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities admitted on the basis of commitments.' It contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, financing facilities, and reconciliation of cash. The period covered is the quarter ended 30 June 2014. The presence of substantive financial data and analysis for a quarter indicates this is a comprehensive interim/quarterly financial report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2014
2014-07-29 English
Communication from Financier NovaQuest 2 pages 131.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 8 July 2014 from Pharmaxis Ltd. It discusses a notice received from a financier (NovaQuest) alleging breach of a financing agreement and the company's response to this allegation. The content focuses on financing issues, potential default events, and implications for future funding and partnerships. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is an update on financing matters and disputes related to capital structure and funding agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4666 characters, which is sufficient for a substantive update rather than a brief announcement. Hence, the classification is CAP with high confidence.
2014-07-07 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.